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Clinical endpoints relevant for relative effectiveness assessment (REA) reflect how 
patients feel, function, or survive. Outcome data requested by health technology assess-
ment (HTA) bodies in Europe to support reimbursement of an anticancer drug are based 
on final endpoints coming from completed comparative phase 3 trials; overall survival 
improvement is the preferred criterion for the demonstration of the patient benefit in this 
field. Recent arrival of new treatments that target identified functional genetic mutations 
(“targeted therapies”) or PD-1/PD-L1,2 axis (“immunotherapies”) and their combinations 
have profoundly changed treatment strategies in cancers as they considerably improve 
patient survival, but also raise new challenges in REA and decision-making process 
in Europe as compared to the REA of “classical” chemotherapies. In addition, recent 
regulatory initiatives to support accelerated clinical development and approval of innova-
tive cancer immunotherapies based on non-final endpoints, such as priority medicines 
through the European Medicines Agency, represent an additional challenge for HTA 
bodies and decision makers. In order to support adequate data generation for REA 
of anticancer drugs and especially for drugs candidates for accelerated assessment 
and early access to market, a close and open dialog of all stakeholders involved in 
development of such drugs is crucial.
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iNtrODUctiON
The choice of adequate endpoints as well as adequate comparator(s) in well-designed clinical trials 
is crucial to support both marketing authorization and reimbursement decisions. Clinical endpoints 
for relative effectiveness assessment (REA) considered relevant for patients measure morbidity, mor-
tality, and health-related quality of life (HRQoL). In the field of oncology, overall survival (OS) data 
coming from comparative phase 3 trials are generally requested by health technology assessment 
(HTA) bodies to demonstrate patient benefit for an anticancer drug.
As compared to classical chemotherapy, cancer immunotherapies and their combinations raise 
many challenges in REA, even when based on endpoints considered relevant by HTA bodies. Recent 
regulatory initiatives to support accelerated clinical development and approval of innovative cancer 
Abbreviations: CHMP, Committee for Medicinal Products for Human Use; EMA, European Medicines Agency; HRQoL, 
health-related quality of life; HTA, health technology assessment; OS, overall survival; PFS, progression-free survival; PRIME, 
priority medicines; REA, relative effectiveness assessment.
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immunotherapies, based on intermediate or surrogate endpoints, 
represent an additional challenge for HTA bodies and decision 
makers in Europe.
reA OF ANticANcer DrUGs – GeNerAL 
reQUireMeNts
Whatever the disease, clinical endpoints for REA recognized 
as endpoints relevant for patients broadly measure mortality, 
morbidity (due to disease or its treatment), and HRQoL; they 
reflect how a patient feels, functions, or survives (1). This defini-
tion of clinical endpoints (2) is accepted by most reimbursement 
agencies in Europe (3). Simultaneous assessment of all relevant 
endpoints is a hallmark of REA; even if a trial is powered on a 
primary endpoint, the added clinical benefit of a new drug will 
be assessed on all endpoints relevant for a disease or its treatment 
(1). Preference is clearly given to long-term or final endpoints (3). 
Surrogate endpoints are accepted only when they are validated, 
i.e., when there is compelling evidence of a clear and consistent 
correlation between the effect of treatment on the surrogate and 
the effect on the final outcome of interest (4). In the field of oncol-
ogy, endpoints generally recognized as relevant for patients are: 
OS improvement (final endpoint), improvement in progression-
free survival, or survival without symptoms, time until the start of 
new treatment, the possibility to access curative alternative treat-
ments (for example surgery or a new chemotherapy), improve-
ment in key disease symptoms (intermediate endpoints), toxicity 
reduction, and improvement or lack of noticeable alteration of 
quality of life.
Overall survival improvement is the preferred criterion by 
HTA bodies in Europe for the demonstration of the benefit of an 
anticancer drug; globally, a survival gain of at least 2–3 months or 
more would be considered appropriate for a new drug versus an 
adequate comparator, even if there is no officially defined thresh-
old (5). In cancers with low mortality, progression-free survival 
(PFS) and (exceptionally) response rates may be acceptable as 
intermediate endpoints.
The role of PFS role is double in this respect: as substitution 
endpoint or as endpoint with an intrinsic value in relation to qual-
ity of life and other clinical benefits (symptoms reduction) and as 
an intermediate clinical endpoint more or less correlated to OS 
when the latter is not available (5). The problem with using PFS 
as an intermediate and/or substitution endpoint is not specific 
to oncology, but it has a particular importance in cancers with 
long survivals. As intermediate endpoints tend to overestimate 
the medical benefit (6), even if validated for a particular tumor 
and stage of disease, OS is clearly preferred by reimbursement 
agencies (5).
The assessment of the added clinical benefit of a new drug 
is always a comparative one; it is based on its comparison to an 
adequate comparator or treatment strategy/ies defined by HTA 
bodies, by using appropriate clinical endpoints, relevant to the 
main characteristics of the disease/condition to treat, the target 
population and the aim of treatment.
Therefore, in the case of an irrelevant comparator, and/or a 
wrong choice of endpoints, or clinically irrelevant difference in 
OS, added benefit may not be granted. In the absence of OS data, 
lower added benefit may be granted if it is based on PFS data only. 
As mature data are requested whenever possible, interim analysis 
is generally not recommended, especially on PFS, but also on OS 
data if too premature.
As REA should support clinical practice guidelines, data 
to support the potential place of the product in the treatment 
pathway (treatment after progression, possibility/effectiveness of 
subsequent treatments) and effectiveness in relevant patient sub-
populations (slowly progressing versus fast progressing patients) 
are also of interest.
reA OF cANcer iMMUNOtHerAPies
As stated, outcome data requested by HTA bodies to support 
reimbursement of anticancer drugs are based on final (“hard”) 
endpoints coming from completed comparative phase 3 trials. In 
addition to OS (final endpoint), other patient-relevant endpoints 
are also assessed (such as time to symptomatic progression, 
symptoms, HRQoL).
The recent arrival of new treatments that target identified 
functional genetic mutations (“targeted therapies”) or PD-1/
PD-L1,2 axis (“immunotherapies”) and their combinations 
have profoundly changed treatment strategies in cancers as they 
considerably improve patient survival, but have also raised new 
challenges in REA and decision-making process in Europe as 
compared to the REA of “classical” chemotherapies. In addi-
tion, recent regulatory initiatives to support accelerated clinical 
development and approval of cancer immunotherapies, based 
on intermediate or surrogate endpoints such as PRIME through 
the EMA, represent an additional challenge for HTA bodies and 
decision makers.
tArGeteD tHerAPies
If we review some recent developments and REAs of targeted 
monotherapies and their combinations in Europe, we shall find 
the following common features: enriched study designs, aimed 
to show superiority, versus reference treatment (chemotherapy 
for targeted monotherapies and targeted monotherapy for com-
bination targeted therapies) on intermediate and final endpoints, 
high response rates, relevant PFS and OS improvements and 
acceptable (or decreased) toxicity (with two targeted drug combi-
nations). Both product development programs and study results 
do not represent a real challenge for REA and reimbursement: 
binary reasoning (presence or absence of mutation), validated 
companion test, existence of regulatory and HTA guidelines on 
drug-biomarker co-development and assessment, clear results, 
and lack of difficulty understanding product effectiveness and 
safety profile, make REA rather straightforward.
iMMUNOtHerAPies
The situation is clearly different with current immunotherapies 
targeting the PD-1/PD-L1,2 axis. The evidence provided by devel-
opers raises challenges at each step of REA: choice of adequate 
population, choice of adequate dose, and assessment of response 
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to treatment. Indeed, despite the hypothesis that the expression 
of PD-L1 on immune and tumor cells is correlated with efficacy, 
different companies have chosen different approaches to define 
target population and support their product effectiveness for the 
same indication (e.g., non-small cell lung cancer): nivolumab was 
tested and approved in overall patient population irrespective of 
PD-1 status and pembrolizumab in PD-1 positive patients (50% 
cutoff) only. For combination immunotherapies, responses have 
been observed regardless of tumor expression of PD-L1 at baseline 
(ipilimumab + nivolumab, tremelimumab + durvalumab)(7).
With regards to the choice of adequate dose, the absence of 
a clear relationship between the dose and antitumor activity 
and toxicity has raised criticisms from the HTA bodies and dif-
ficulties in REA; the choice of dose remains an issue for further 
product development and use [e.g., further study requested by 
the food and drug administration (FDA) to compare ipilimumab 
3 mg/kg – approved dose and 10 mg/kg Q3W – unapproved dose, 
tested in the adjuvant setting in melanoma]. The choice of dose(s) 
is even more difficult for combination immunotherapies (7), 
and may involve different scenarios, the most frequent being to 
administrate one product at fixed dose and the other at increasing 
doses and assess tumor growth inhibition.
Except for OS, the assessment of response to treatment to 
immunotherapies is not straightforward due to pseudo progres-
sions and their impact on the assessment of intermediate effec-
tiveness endpoints (timing of assessment, adaptation of existing 
tools, characterization of progression, and decision to allow for 
cross over or change treatment).
Low response rates, long duration of response, and long OS in 
some patients, all improved with combination immunotherapies 
but with much higher toxicity and high costs, render decision-
making rather difficult both in curative and supposedly also in 
an adjuvant setting.
AcceLerAteD AssessMeNt AND 
eArLY Access tO MArKet
As the first step to market access, a new medicinal product 
requires marketing authorization from a regulatory agency, based 
on its acceptable quality, safety, and efficacy in a given patient 
population, in comparison to placebo and/or (an) appropriate 
comparator(s) in pre-marketing clinical trials. The second step 
to market access to support a reimbursement decision is the REA 
that compares the benefits and harms of a new drug in a target 
population with one or more alternative interventions (e.g., stand-
ard of care), evaluating whether a new treatment has an added 
benefit or is equivalent to existing alternatives for achieving the 
desired results when provided under the usual circumstances of 
health-care practice.
Both marketing authorization issued by the EMA and posi-
tive reimbursement decisions issued by national authorities are 
necessary for market access of a new drug.
Current European pharmaceutical legislation includes differ-
ent possibilities aimed at facilitating patients’ early access to new 
drugs that address public health needs, such as an accelerated 
assessment procedure, a conditional marketing authorization, 
and the possibility of a compassionate use opinion by the 
committee for human medicinal products (CHMP), defining 
at European level the criteria and conditions for the use of 
non-authorized medicinal products made available to patients 
through national patient access programs (prior to a marketing 
authorization).1
To optimize accelerated assessment, EMA has launched the 
PRIority Medicines (PRIME) program2 to support the develop-
ment of innovative medicinal products (such as cancer immuno-
therapies and/or targeted therapies), which is supposed to have a 
major public health interest in conditions where there is unmet 
medical need. A major therapeutic advantage to patients should 
be demonstrated through a clinically meaningful improvement of 
efficacy, and/or an impact on the prevention, onset, or duration 
of the condition. Access to the PRIME scheme will depend on 
both the magnitude of the treatment effect, which could include 
duration of the effect, and the relevance of the observed clinical 
outcome.3,4
Early interaction between the applicant and multiple stake-
holders, involving EMA, HTA bodies, and patients, on key deci-
sion points/issues for the preparation of marketing authorization 
application and reimbursement dossiers, is foreseen to ensure the 
generation of a robust data package and to facilitate timely access 
to patients. Existing scientific advice procedures (independent or 
integrated regulatory and HTA advice, either on the national or 
European level) may be used for this purpose (8).5
DiscUssiON
The improvement in OS remains a gold standard for REA to inform 
reimbursement decisions for an anticancer drug. Intermediate 
endpoints such as response rate, duration of response, and PFS are 
not easily accepted as predictors of clinical benefit and assessed 
(only) in the absence of OS data. Surrogacy of these endpoints 
to predict OS depends on tumor type and stage of disease, as 
well as on the therapeutic agent used. Delayed responses and 
pseudo-progressions on some immunotherapies make this task 
even more difficult. With the current HTA mind-set, limited 
development programs that might be sufficient for an accelerated 
1 EMA/531801/2015. Development support and regulatory tools for early access 
to medicines. Available from: http://www.ema.europa.eu/docs/en_GB/docu-
ment_library/Other/2016/03/WC500202631.pdf.
2 EMA/89921/2016. Launch of PRIME – paving the way for promising medicines 
for patients. Available from: http://www.ema.europa.eu/docs/en_GB/docu-
ment_library/Press_release/2016/03/WC500202669.pdf.
3 EMA/191104/2015. European Medicines Agency Guidance for applicants seeking 
access to PRIME scheme. Available from: http://www.ema.europa.eu/docs/en_GB/
document_library/Other/2016/03/WC500202630.pdf.
4 EMA/CHMP/57760/2015. Enhanced early dialogue to facilitate accelerated 
assessment of PRIority MEdicines (PRIME). Available from: http://www.ema.
europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guide-
line/2016/03/WC500202636.pdf.
5 European Medicines Agency. Guidance for Applicants seeking scientific advice 
and protocol assistance EMA/691788/2010 Rev. 7. Available from: http://www.ema.
europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guide-
line/2009/10/WC500004089.pdf.
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assessment and regulatory approval might not be sufficient to 
support reimbursement. A recent survey on reimbursement 
status of medicines granted conditional approval shows that 
HTA decisions still remain independent on the regulatory route 
of approval and consider only data available to support REA and 
not the regulatory approval pathway (9).
It is supposed that the arrival of different drug combinations 
in the rapidly evolving field of cancer immunotherapies and 
better understanding of the synergy between different treatment 
modalities, relationships between responses to treatment, dura-
tions of response, toxicities and survival, will ultimately influence 
REA reasoning and reimbursement decisions. In addition, the 
establishment of the surrogacy between intermediate endpoints 
and OS might allow for earlier access to market based on non-
final endpoints.
An open dialog of all stakeholders involved in the devel-
opment of these products in order to support adequate data 
generation for early assessment and access to market is crucial 
in this respect. In general, the choice of adequate endpoints 
and comparators to support both (accelerated) assessment and 
(early) access to market is crucial in any drug development. 
The recent analyses of parallel EMA – HTA scientific advice 
with regard to requests for the trial population, study design, 
endpoints, and comparators, show an agreement, important 
for trial population and study design and rather weak for the 
choice of endpoints and comparator(s) (10)6; on the contrary, 
the agreement among HTA bodies was rather high on most 
items (10).
Despite divergences in regulatory and pricing/reimbursement 
requests for data generation, it is postulated that these can be 
integrated within global product development and outcomes for 
benefit-risk and REA, standardized in order to be able to “file the 
same and propose the same,” both for regulatory and reimburse-
ment purposes.
This does not guarantee that a drug will be reimbursed – its 
reimbursement status will probably vary from one country to 
another. However, there is a hope that decreasing uncertainty of 
assessment will ultimately facilitate market access and patient care.
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